Boston Scientific (NYSE:BSX) today said it won CE Mark approval in the European Union for a component of its Vercise deep brain stimulation device that allows physicians to “steer” electric currents to different parts of the brain.
Natick, Mass.-based Boston Scientific 1st won CE Mark approval for Vercise in 2012. The most recent mark covers its Vercise primary cell device, which in conjunction with a directional lead, is designed to “provide precise neural targeting” in treating Parkinson’s disease, dystonia and essential tremor, the company said.
“This new system exemplifies the Boston Scientific commitment to advancing DBS therapy and providing impactful and transformative technology to reach a broader range of patients suffering from these debilitating diseases,” neuromodulation president Maulik Nanavaty said in prepared remarks. “Our clinical evidence, unique software solution, and expanded portfolio, now with both rechargeable and non-rechargeable devices, enable physicians to provide their patients with a tailored solution.”
A U.S. clinical trial of the rechargeable Vercise device, launched in 2012, is designed to evaluate the safety and efficacy of the device in improving motor function and quality of life for patients with Parkinson’s.
from MassDevice http://ift.tt/1Nk5PBf
Cap comentari:
Publica un comentari a l'entrada